Kazia Therapeutics Limited ADR (KZIA) — Titan Protect Analysis

KZIA

Kazia Therapeutics Limited ADR

Healthcare · ·

$10.99

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$138M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-986.48

Based on estimated future earnings — lower means cheaper

Rev Growth

+312.4%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-106.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.50

+87% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 3 analysts covering this stock

About Kazia Therapeutics Limited ADR

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphom

https://www.kaziatherapeutics.com

Country: Australia Employees: 6 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.725

Good returns relative to risk taken

Kelly Fraction

0.0396

Modest edge detected — smaller position warranted

Calmar Ratio

-0.086

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-8.2%

Historical annualised return based on price data

Max Drawdown

-95.0%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.23

Significantly more volatile than the market

52W High

$17.40

37% below the year high

52W Low

$4.65

136% above the year low

Avg Volume

205,100

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-7.63

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.21

Conservative use of debt — low financial risk

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-14,641.0%

Profit from core operations before interest and tax

Free Cash Flow

$1M

Positive — the business generates more cash than it spends

Revenue (TTM)

$2M

Total revenue over the last 12 months

Net Income

$-22,800,680

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$24.95

Target Median

$20.50

Target Low

$18.45

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go